Navigation Links
PDI, Inc. Announces Client FDA Product Approval Related to Previously Disclosed Contract
Date:7/18/2012

PARSIPPANY, N.J., July 18, 2012 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today announced that the client related to a previously disclosed contract has received FDA approval to market its product. PDI had entered into an agreement with that client to provide an array of promotional services for this product, including but not limited to a dedicated sales team, as well as teledetailing and digital communications through PDI's Group DCA division.

On May 24, 2012, PDI announced that it signed a contract, which was subject to FDA approval of the client's product, with this client. The contract is expected to generate total revenue to PDI of approximately $57 million over the life of the two-year agreement, with $10-$11 million to be recorded over the second half of 2012.

"We look forward to assisting our client in the launch of its newly FDA-approved product," said Nancy Lurker, Chief Executive Officer of PDI, Inc. "Our wide range of educational and promotional support will help the client effectively reach patients and physicians with this important new medicine."

About PDI, Inc.
PDI is a leading health care commercialization company providing superior insight-driven, integrated multi-channel message delivery to established and emerging health care companies. The company is dedicated to enhancing engagement with health care practitioners and optimizing commercial investments for its clients by providing strategic flexibility, full product commercialization services, innovative multi-channel promotional solutions, and sales and marketing expertise. For more information, please visit the company's website at http://www.pdi-inc.com.

Forward-Looking Statements
This press release contains forward-looking statements regarding future events and financial performance. These statements are based on current expectations and assumptions involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond PDI's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause PDI's actual results to be materially different from those expressed or implied by any forward-looking statement.

For example, with respect to statements regarding projections of future revenues, growth and profitability, actual results may differ materially from those set forth in this release based on the loss, early termination or significant reduction of any of our existing service contracts, the failure to meet performance goals in PDI's incentive-based arrangements with customers or the inability to secure additional business. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in PDI's periodic filings with the Securities and Exchange Commission, including without limitation, PDI's Annual Report on Form

10-K for the year ended December 31, 2011, and PDI's subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, PDI undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

 

 

 

 


'/>"/>
SOURCE PDI, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Pharmaceuticals Announces Closing of Public Offering
2. Boston Scientific Announces Promising Clinical Data on New Products at the International Spine Intervention Society 20th Annual Scientific Meeting
3. Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
4. Equinoxo2 Medical Announces Distribution of a New Portable Device
5. Medica Announces Global Release of the EasyCell Assistant Analyzer for Hematology Laboratories
6. Curemark Announces Executive Promotions
7. Merit Medical Systems Announces Earnings Release Date/Time And Conference Call Information For The Second Quarter Ended June 30, 2012
8. Physician-Patient Alliance for Health & Safety Announces New Expert Checklist for Facilitating Safety of Hospital-Based Intravenous Patient-Controlled Analgesia Pumps
9. The SSI Group, Inc. President and CEO Bobby Smith Announces Retirement
10. PTCB Announces New Educator Program
11. ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
(Date:9/19/2017)... 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically ... announced three leadership team developments today:   ... ... Tom ... Veteran medical device executive Josh Stopek , PhD, who ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , the ... chains, has published the first annual edition of its Global CSR Risk ... 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly ... ... Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to take certain medications ... from Austin, Texas, has identified a solution. , She developed a prototype for MOTION ... As such, it eliminates the need to turn on a light when taking medication ...
(Date:10/13/2017)... EDWARDSVILLE, Ill. (PRWEB) , ... ... ... University Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and ... educated healthcare professionals on guideline updates for the primary prevention of cardiovascular ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) ... a collection of specialty vendors and unique items from across the nation, this holiday-themed ... and wellness services offered by the VNA. The boutique will be open Saturday, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
Breaking Medicine News(10 mins):